Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
In clinical trials, retatrutide produced 24.2% weight loss at 48 weeks compared to tirzepatide's 20.9% at 72 weeks
Avoid skipping meals, even if your appetite feels low earlier in the day
doi:10.7759/cureus.5604
Ongoing research is examining several important questions regarding tirzepatide's long-term safety profile: Thyroid cancer surveillance : Prospective monitoring of thyroid-related adverse events in large patient cohorts Pancreatic safety : Evaluation of pancreatitis and pancreatic cancer risk with extended exposure Gallbladder disease : Assessment of cholecystitis and cholelithiasis incidence with rapid weight loss Comparative safety : Head-to-head comparisons with other incretin-based therapies The American Diabetes Association and American Association of Clinical Endocrinology (AACE) continue to recommend tirzepatide as an effective treatment option for type 2 diabetes and obesity, with the understanding that ongoing surveillance will further clarify its long-term safety profile
